Company intelligence / Profile preview
Eascra Biotech
- Ownership
- Private
- Development stage
- Preclinical
Overview
The company has demonstrated promising preclinical results showing effective penetration of difficult tissues by their nanoparticles. Initial studies include stopping cartilage degradation in arthritis models. They are also exploring manufacturing nanoparticles in space to enhance product quality. Collaborations with NASA and other agencies support advanced R&D efforts.
No detailed clinical trial results published yet.
- Therapeutic areas
- OncologyRheumatology
- Modalities
- Nanoparticle-based delivery systems (Janus Base Nanoparticles - JBNps)RNA therapeutics including siRNA, mRNAGene editing materials such as Cas9Proteins and peptides deliveryInjectable scaffolds for tissue regeneration
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Eascra Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eascra Biotech.